期刊文献+

非小细胞肺癌中EGFR基因突变与ERCC1、Ki-67表达及临床病理特征的关系 被引量:11

EGFR gene mutation status,ERCC1 and Ki-67 protein expression in non-small cell lung cancer and relationship with clinicopathologic features
下载PDF
导出
摘要 目的探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)中EGFR基因突变与切除修复交叉互补基因1(excision repair cross-complementation group 1,ERCC1)、Ki-67蛋白表达及其临床意义。方法采用DNA测序法检测EGFR基因突变,免疫组化En Vision法检测ERCC1、Ki-67蛋白表达,分析与临床病理特征的关系。结果 EGFR基因突变率为49.1%(143/291),多见于女性、不吸烟、腺癌患者。EGFR基因突变在腺癌的不同亚型中差异有显著性(P=0.008);EGFR基因突变组肿瘤直径的中位数小于野生型组(P=0.020);EGFR基因突变与患者年龄、淋巴结有无癌转移无相关性(P>0.050);鳞状细胞癌中ERCC1阳性率高于腺癌(P=0.039)。Ki-67表达与肺癌分化程度有关,低分化高于高、中分化(P=0.010);ERCC1、Ki-67表达与EGFR基因突变无相关性(P>0.050)。结论 EGFR基因突变与NSCLC患者性别、组织学类型、分化程度等相关,存在多种突变。EGFR基因突变与ERCC1、Ki-67表达无相关性。 Purpose To study the status of EGFR mutations and the expression of excision repair cross-complementation group 1 ( ER-CC1) and Ki-67 protein in patients with non-small cell lung cancer (NSCLC) and to examine the relationship between their expression and clinicopathologic features. Methods EGFR mutations were analyzed with DNA sequencing, and the expression of ERCC1 and Ki-67 protein was examined by immunohistochemistry EnVision. The relationship of EGFR mutations with the expression of ERCC1and Ki-67 and the clinicopathological features were analyzed. Results EGFR mutations were detected in 143 (143/291, 49. 1%) of the 291 specimens. EGFR mutations were found more frequently in women, non-smokers and adenocarcinoma. The difference of EGFR muta-tion rate between the histological subtypes according to the IASLC/ATS/ERS classification of lung adenocarcinoma was significantly ( P=0. 008). The mean tumor diameter was smaller in patients with EGFR mutations than in those with wild-type EGFR (P=0. 020). EGFR mutations were not related to age, lymph node metastasis. However, EGFR mutations were not related to the expression of ER-CC1 and Ki-67 protein (P〉0. 050). Conclusions EGFR mutation is closely linked to several clinicopathological factors, such as gender, differentiation, and histological subtype. There is heterogeneity of EGFR mutation in patients with NSCLC. EGFR mutations were not related to the expression of ERCC1 and Ki-67 protein.
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2015年第7期759-763,共5页 Chinese Journal of Clinical and Experimental Pathology
基金 863重点项目计划(2011AA02A110)
关键词 肺肿瘤 突变 ERCC1 KI-67 EGFR lung neoplasm EGFR mutation ERCC1 Ki-67
  • 相关文献

参考文献20

  • 1Herbst R S, Heymach J V, Lippman S M. Lung cancer[J]. N Engl J Med, 2008,359(13) :1367 -80.
  • 2Roth J A, Carlson J J. Prognostic role of ERCC1 in advanced non- small-cell lung cancer: a systematic review and meta-analysis[ J]. Clin Lung Cancer, 2011,12(6) :393 -401.
  • 3Yamashita F, Azuma K, Yoshida T, et al. Prognostic value of EGFR mutation and ERCCI in patients with non-small cell lung cancer undergoing platinum-based chemothera [ J ]. PLoS One, 2013,8(8) :e71356.
  • 4Belani C P, Goss G, Blumenschein G Jr. Recent clinical develop- ments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC) [J]. Cancer Treat Rev, 2012,38(3) :173 - 84.
  • 5Paez J G, Janne P A, Lee J C, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy [ J ]. Science, 2004,304 (5676) : 1497 - 500.
  • 6Fukuoka M, Wu Y L, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitax- el in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) [J]. J Clin Oncol, 2011,29(21 ) :2866 -74.
  • 7Vilmar A C, Sorensen J B. Customising chemotherapy in advanced non-small cell lung cancer: daily practice and perspectives [ J]. Eur Respir Rev, 2011,20(119) :45 -52.
  • 8Gonzalez-Moles M A, Ruiz-Avita I, Gil-Montoya J A, et al. Anal- ysis of Ki-67 expression in oral squamous cell carcinoma: why Ki- 67 is not a prognostic indicator [ J ]. Oral Oncol, 2010,46 (7) : 525 - 30.
  • 9Dowsett M, Nielsen T O, A'Hern R, et al. Assessment of Ki-67 in breast cancer: recommendations from the international Ki-67 in breast cancer working group[J]. J Natl Cancer Inst, 2011,103 (22) :1656 -64.
  • 10Pao W, Miller V A, Politi K A, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain [ J ]. PLoS Med, 2005,2 (3) :e73.

同被引文献100

引证文献11

二级引证文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部